It has been more than 30 years since the Bosniak classification of cystic renal masses was first proposed (1). This CT-based classification was introduced in 1986 and originally divided cystic renal masses into one of four classes after exclusion of infectious, inflammatory, and vascular etiologies (Table 1) (1). Since then, refinements have reduced the number of benign masses in Bosniak class III (2-9). For example, Bosniak IIF (where the F is for follow-up) was added for cystic masses with many thin (or minimally thickened) septa with "perceived" enhancement, large (.3 cm) homogeneous nonenhancing hyperattenuating masses, and masses with thick or non-border-forming calcification.Bosniak summarized these changes in 2012 and contended that Bosniak I and II masses were "clearly benign," Bosniak IV masses were "clearly malignant," Bosniak IIF masses were "probably benign," and Bosniak III masses were "indeterminate" (approximately half were malignant and half were not) (9). These adaptations enabled radiologists and urologists to render specific management recommendations: Bosniak I and II masses have been ignored, Bosniak IIF masses have been followed, and Bosniak III and IV masses historically have been treated unless substantial comorbidities or limited life expectancy would warrant observation instead (10-12).
Desmoids are locally aggressive fibrous tumors with a tendency to recur. Desmoids can be intraabdominal, in the abdominal wall, or extraabdominal. Complications, such as compression or invasion of adjacent structures, and abscess formation can occur. Treatment options include observation, local treatment (surgery, radiotherapy), or systemic therapy (conventional chemotherapy, molecular targeted agents).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.